PharmaBiome raises €1.6M Bridge round
8 July 2020· Schlieren, Switzerland· health, biotechnology, microbiome, drug_development, b2b, deep_tech
To advance preclinical development of lead product PB002 for ulcerative colitis (UC) and strengthen production and lead identification platforms. The company also aims to initiate the first pilot clinical trial with PB002 in UC and emerge as a leading European company in the microbiome field.
Investors
LeadThomas Meier
Also participating
Patrik Forrer
About PharmaBiome
Stage
Series A
Headquarters
Schlieren, Switzerland
Founded
2015
Team Size
6–20
Sectors
healthbiotechnologymicrobiomedrug_developmentb2bdeep_tech